Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS

Molecular Therapy Nucleic Acids

Volumn 8, Issue , 2017, Pages 184-197

  Kanaan, Nicholas M ^a,b   Sellnow, Rhyomi C ^a   Boye, Sanford L ^c   Coberly, Ben ^a,d   Bennett, Antonette ^c   Agbandje McKenna, Mavis ^c   Sortwell, Caryl E ^a,b   Hauswirth, William W ^c   Boye, Shannon E ^c   Manfredsson, Fredric P ^a,b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b St Mary's Mercy Medical Center   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

AAV; capsid; CNS; mutant

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HEPARAN SULFATE; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; THREONINE; TYROSINE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 8; ADULT; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL COUNTING; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DORSAL HIPPOCAMPUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RAT; SEROTYPE; TROPISM; VIRUS CAPSID; VIRUS PARTICLE; VOLUMETRY;

EID: 85029280741     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1016/j.omtn.2017.06.011     Document Type: Article

References (57)

1. Kantor, B., Bailey, R.M., Wimberly, K., Kalburgi, S.N., Gray, S.J., Methods for gene transfer to the central nervous system. Adv. Genet. 87 (2014), 125–197.
2. Manfredsson, F.P., Mandel, R.J., Development of gene therapy for neurological disorders. Discov. Med. 9 (2010), 204–211.
3. Marks, W.J. Jr., Baumann, T.L., Bartus, R.T., Long-term safety of patients with Parkinson's disease receiving rAAV2-neurturin (CERE-120) gene transfer. Hum. Gene Ther. 27 (2016), 522–527.
4. Bartus, R.T., Herzog, C.D., Chu, Y., Wilson, A., Brown, L., Siffert, J., Johnson, E.M. Jr., Olanow, C.W., Mufson, E.J., Kordower, J.H., Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 26 (2011), 27–36.
5. Polinski, N.K., Gombash, S.E., Manfredsson, F.P., Lipton, J.W., Kemp, C.J., Cole-Strauss, A., Kanaan, N.M., Steece-Collier, K., Kuhn, N.C., Wohlgenant, S.L., Sortwell, C.E., Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain. Neurobiol. Aging 36 (2015), 1110–1120.
6. Zhong, L., Li, B., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R.W., Zolotukhin, I., Warrington, K.H. Jr., Weigel-Van Aken, K.A., et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA 105 (2008), 7827–7832.
7. Maheshri, N., Koerber, J.T., Kaspar, B.K., Schaffer, D.V., Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24 (2006), 198–204.
8. Grimm, D., Lee, J.S., Wang, L., Desai, T., Akache, B., Storm, T.A., Kay, M.A., In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (2008), 5887–5911.
9. Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20 (2012), 443–455.
10. Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology 381 (2008), 194–202.
11. Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.H., Chiodo, V., Pang, J.J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A.S., Hauswirth, W.W., High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol. Ther. 17 (2009), 463–471.
12. Nicolson, S.C., Samulski, R.J., Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J. Virol. 88 (2014), 4132–4144.
13. Xiao, P.J., Li, C., Neumann, A., Samulski, R.J., Quantitative 3D tracing of gene-delivery viral vectors in human cells and animal tissues. Mol. Ther. 20 (2012), 317–328.
14. Xiao, P.J., Samulski, R.J., Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J. Virol. 86 (2012), 10462–10473.
15. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., Srivastava, A., Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?. PLoS ONE, 8, 2013, e59142.
16. Pandya, J., Ortiz, L., Ling, C., Rivers, A.E., Aslanidi, G., Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol. Cell Biol. 92 (2014), 116–123.
17. Summerford, C., Samulski, R.J., Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72 (1998), 1438–1445.
18. Boye, S.L., Bennett, A., Scalabrino, M.L., McCullough, K.T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., Boye, S.E., Impact of heparan sulfate binding on transduction of retina by recombinant adeno-associated virus vectors. J. Virol. 90 (2016), 4215–4231.
19. Perabo, L., Goldnau, D., White, K., Endell, J., Boucas, J., Humme, S., Work, L.M., Janicki, H., Hallek, M., Baker, A.H., Büning, H., Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism. J. Virol. 80 (2006), 7265–7269.
20. Shi, X., Fang, G., Shi, W., Bartlett, J.S., Insertional mutagenesis at positions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17 (2006), 353–361.
21. Kay, C.N., Ryals, R.C., Aslanidi, G.V., Min, S.H., Ruan, Q., Sun, J., Dyka, F.M., Kasuga, D., Ayala, A.E., Van Vliet, K., et al. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS ONE, 8, 2013, e62097.
22. Choudhury, S.R., Hudry, E., Maguire, C.A., Sena-Esteves, M., Breakefield, X.O., Grandi, P., Viral vectors for therapy of neurologic diseases. Neuropharmacology 120 (2017), 63–80.
23. Reimsnider, S., Manfredsson, F.P., Muzyczka, N., Mandel, R.J., Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol. Ther. 15 (2007), 1504–1511.
24. Aschauer, D.F., Kreuz, S., Rumpel, S., Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS ONE, 8, 2013, e76310.
25. Manfredsson, F.P., Tumer, N., Erdos, B., Landa, T., Broxson., C.S., Sullivan, L.F., Rising, A.C., Foust, K.D., Zhang, Y., Muzyczka, N., et al. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol. Ther. 17 (2009), 980–991.
26. Liu, G., Chen, Y.H., He, X., Martins, I., Heth, J.A., Chiorini, J.A., Davidson, B.L., Adeno-associated virus type 5 reduces learning deficits and restores glutamate receptor subunit levels in MPS VII mice CNS. Mol. Ther. 15 (2007), 242–247.
27. Hildinger, M., Auricchio, A., Gao, G., Wang, L., Chirmule, N., Wilson, J.M., Hybrid vectors based on adeno-associated virus serotypes 2 and 5 for muscle-directed gene transfer. J. Virol. 75 (2001), 6199–6203.
28. Asokan, A., Schaffer, D.V., Samulski, R.J., The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20 (2012), 699–708.
29. Chen, H., McCarty, D.M., Bruce, A.T., Suzuki, K., Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J. Neurosci. Res. 55 (1999), 504–513.
30. Feng, X., Eide, F.F., Jiang, H., Reder, A.T., Adeno-associated viral vector-mediated ApoE expression in Alzheimer's disease mice: low CNS immune response, long-term expression, and astrocyte specificity. Front. Biosci. 9 (2004), 1540–1546.
31. Rosario, A.M., Cruz, P.E., Ceballos-Diaz, C., Strickland, M.R., Siemienski, Z., Pardo, M., Schob, K.L., Li, A., Aslanidi, G.V., Srivastava, A., et al. Microglia-specific targeting by novel capsid-modified AAV6 vectors. Mol. Ther. Methods Clin. Dev., 3, 2016, 16026.
32. Ryals, R.C., Boye, S.L., Dinculescu, A., Hauswirth, W.W., Boye, S.E., Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines. Mol. Vis. 17 (2011), 1090–1102.
33. Li, M., Jayandharan, G.R., Li, B., Ling, C., Ma, W., Srivastava, A., Zhong, L., High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. Hum. Gene Ther. 21 (2010), 1527–1543.
34. Benskey, M.J., Kuhn, N.C., Galligan, J.J., Garcia, J., Boye, S.E., Hauswirth, W.W., Mueller, C., Boye, S.L., Manfredsson, F.P., Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants. Mol. Ther. 23 (2015), 488–500.
35. Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., Chapman, M.S., The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99 (2002), 10405–10410.
36. Brightman, M.W., The brain's interstitial clefts and their glial walls. J. Neurocytol. 31 (2002), 595–603.
37. Shi, W., Bartlett, J.S., RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7 (2003), 515–525.
38. Xing, G., Zhang, L., Zhang, L., Heynen, T., Li, X.L., Smith, M.A., Weiss, S.R., Feldman, A.N., Detera-Wadleigh, S., Chuang, D.M., Post, R.M., Rat nurr1 is prominently expressed in perirhinal cortex, and differentially induced in the hippocampal dentate gyrus by electroconvulsive vs. kindled seizures. Brain Res. Mol. Brain Res. 47 (1997), 251–261.
39. Pillay, S., Meyer, N.L., Puschnik, A.S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L.T., Wosen, J.E., Nagamine, C.M., Chapman, M.S., Carette, J.E., An essential receptor for adeno-associated virus infection. Nature 530 (2016), 108–112.
40. Burger, C., Gorbatyuk, O.S., Velardo, M.J., Peden, C.S., Williams, P., Zolotukhin, S., Reier, P.J., Mandel, R.J., Muzyczka, N., Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10 (2004), 302–317.
41. McFarland, N.R., Lee, J.S., Hyman, B.T., McLean, P.J., Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J. Neurochem. 109 (2009), 838–845.
42. Taymans, J.M., Vandenberghe, L.H., Haute, C.V., Thiry, I., Deroose, C.M., Mortelmans, L., Wilson, J.M., Debyser, Z., Baekelandt, V., Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum. Gene Ther. 18 (2007), 195–206.
43. Klein, R.L., Dayton, R.D., Leidenheimer, N.J., Jansen, K., Golde, T.E., Zweig, R.M., Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol. Ther. 13 (2006), 517–527.
44. Watakabe, A., Ohtsuka, M., Kinoshita, M., Takaji, M., Isa, K., Mizukami, H., Ozawa, K., Isa, T., Yamamori, T., Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex. Neurosci. Res. 93 (2015), 144–157.
45. Grabinski, T.M., Kneynsberg, A., Manfredsson, F.P., Kanaan, N.M., A method for combining RNAscope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures. PLoS ONE, 10, 2015, e0120120.
46. Leone, P., Shera, D., McPhee, S.W., Francis, J.S., Kolodny, E.H., Bilaniuk, L.T., Wang, D.J., Assadi, M., Goldfarb, O., Goldman, H.W., et al. Long-term follow-up after gene therapy for canavan disease. Sci. Transl. Med., 4, 2012, 165ra163.
47. Rafii, M.S., Baumann, T.L., Bakay, R.A., Ostrove, J.M., Siffert, J., Fleisher, A.S., Herzog, C.D., Barba, D., Pay, M., Salmon, D.P., et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 10 (2014), 571–581.
48. Marks, W.J. Jr., Bartus, R.T., Siffert, J., Davis, C.S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9 (2010), 1164–1172.
49. Polinski, N.K., Manfredsson, F.P., Benskey, M.J., Fischer, D.L., Kemp, C.J., Steece-Collier, K., Sandoval, I.M., Paumier, K.L., Sortwell, C.E., Impact of age and vector construct on striatal and nigral transgene expression. Mol. Ther. Methods Clin. Dev., 3, 2016, 16082.
50. Peden, C.S., Manfredsson, F.P., Reimsnider, S.K., Poirier, A.E., Burger, C., Muzyczka, N., Mandel, R.J., Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Mol. Ther. 17 (2009), 524–537.
51. Benskey, M.J., Sandoval, I.M., Manfredsson, F.P., Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield. Hum. Gene Ther. Methods 27 (2016), 32–45.
52. Zolotukhin, S., Byrne, B.J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., Summerford, C., Samulski, R.J., Muzyczka, N., Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6 (1999), 973–985.
53. Benskey, M.J., Manfredsson, F.P., Intraparenchymal stereotaxic delivery of rAAV and special considerations in vector handling. Methods Mol. Biol. 1382 (2016), 199–215.
54. Manfredsson, F.P., Burger, C., Rising, A.C., Zuobi-Hasona, K., Sullivan, L.F., Lewin, A.S., Huang, J., Piercefield, E., Muzyczka, N., Mandel, R.J., Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol. Ther. 17 (2009), 1857–1867.
55. Gundersen, H.J., Jensen, E.B., The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147 (1987), 229–263.
56. Carrillo-Tripp, M., Shepherd, C.M., Borelli, I.A., Venkataraman, S., Lander, G., Natarajan, P., Johnson, J.E., Brooks, C.L. 3rd, Reddy, V.S., VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 37 (2009), D436–D442.
57. Xiao, C., Rossmann, M.G., Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 158 (2007), 182–187.